openPR Logo
Press release

Non-Alcoholic Steatohepatitis Key Players - AstraZeneca Plc, BASF SE, CymaBay Therapeutics Inc, and Daiichi Sankyo Co Ltd Market Analysis & Forecast 2018-2022

03-01-2018 10:22 AM CET | Health & Medicine

Press release from: WiseGuy Research consultants Pvt Ltd.

/ PR Agency: WISEGUY RESEARCH CONSULTANTS PVT LTD
Non-Alcoholic Steatohepatitis 

Non-Alcoholic Steatohepatitis 

Non-Alcoholic Steatohepatitis 

Overview

Non-alcoholic steatohepatitis (NASH) is liver inflammation caused by a buildup of fat in the liver. NASH can get worse and cause scarring of the liver, which leads to cirrhosis. Symptoms of NASH include fatigue, weight loss for no clear reason, general weakness and an ache in the upper right part of belly. Risk factors include obesity, type 2 diabetes, high cholesterol and high triglycerides and metabolic syndrome.

Click here for sample report @ https://www.wiseguyreports.com/sample-request/2811463-non-alcoholic-steatohepatitis-nash-pipeline-review-h1-2018

Top Companies mentioned

AstraZeneca Plc

BASF SE

CymaBay Therapeutics Inc

Daiichi Sankyo Co Ltd

Viking Therapeutics Inc

Zebra Discovery Ltd

Non-Alcoholic Steatohepatitis Industry Major Outlook

Pharmaceutical and Healthcare latest pipeline guide Non-Alcoholic Steatohepatitis   - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Non-Alcoholic Steatohepatitis  , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Non-Alcoholic Steatohepatitis (NASH) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 32, 28, 6, 84, 35 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.

Non-Alcoholic Steatohepatitis pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Non-Alcoholic Steatohepatitis - Competitive Analysis

Key players are making innovative developments in Non-Alcoholic Steatohepatitis industry.  The same will help in improving the market performance. Heavy investments are made by major players in the R&D sector

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Non-Alcoholic Steatohepatitis.

The pipeline guide reviews pipeline therapeutics for Non-Alcoholic Steatohepatitis by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. 

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Non-Alcoholic Steatohepatitis therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Non-Alcoholic Steatohepatitis therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 

The pipeline guide reviews latest news related to pipeline therapeutics for Non-Alcoholic Steatohepatitis.

.Continued

For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/2811463-non-alcoholic-steatohepatitis-nash-pipeline-review-h1-2018

Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available. We also provide COTS (Commercial off the Shelf) business sector reports as custom exploration agreeing your particular needs.

WISEGUY RESEARCH CONSULTANTS PVT LTD
Office No. 528, Amanora Chambers
Pune - 411028
Maharashtra, India

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Non-Alcoholic Steatohepatitis Key Players - AstraZeneca Plc, BASF SE, CymaBay Therapeutics Inc, and Daiichi Sankyo Co Ltd Market Analysis & Forecast 2018-2022 here

News-ID: 962143 • Views:

More Releases from WiseGuy Research consultants Pvt Ltd.

Beauty Drinks Market and its Future Outlook and Trend During the Period of 2019 – 2025
Beauty Drinks Market and its Future Outlook and Trend During the Period of 2019 …
Global Beauty Drinks Market Research Report 2019 Summary: - Wiseguyreports.Com Adds “Beauty Drinks - Market Demand, Growth, Opportunities, Manufacturers and Analysis of Top Key Players to 2025” To Its Research Database. Overview: Beauty drinks refer to both carbonated and non-carbonated beverages, which is used to retain natural beauty during aging. The beauty drinks contain various vitamins, minerals, amino acids, and antioxidants. It aids to support diets by encouraging metabolism. The global beauty drinks market
Global Capsule Endoscopy Treatment Solutions Market 2020: key Vendors, Trends, A …
Summary A New Market Study, titled “Capsule Endoscopy Treatment Solutions Market Upcoming Trends, Growth Drivers and Challenges” has been featured on WiseGuyReports. This report provides in depth study of “Capsule Endoscopy Treatment Solutions Market” using SWOT analysis i.e. Strength, Weakness, Opportunities and Threat to the organization. The Capsule Endoscopy Treatment Solutions Market report also provides an in-depth survey of key players in the market which is based on the various objectives of an organization such
Data Center Colocation Market 2019: Size, Share, Demand, Trends, Growth and 2025 …
Global Data Center Colocation Industry New Study On “2019-2025 Data Center Colocation Market Global Key Player, Demand, Growth, Opportunities and Analysis Forecast” Added to Wise Guy Reports Database Data center operators face an increasing need for scalable data center infrastructure, which enables the scaling of critical data center components as and when the demand increases. The data center colocation provides data center space, along with the power and cooling infrastructure, which address
Temperature Logger Market 2019 Trends, Research, Analysis & Review Forecast 2025
Global Temperature Logger Industry New Study On “2019-2025 Temperature Logger Market Global Key Player, Demand, Growth, Opportunities and Analysis Forecast” Added to Wise Guy Reports Database This report studies the global Temperature Logger market status and forecast, categorizes the global Temperature Logger market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, and other regions (India, Southeast Asia). The

All 5 Releases


More Releases for Steatohepatitis

Nonalcoholic Steatohepatitis (NASH) Market Massive Growth opportunity Ahead
Introduction Nonalcoholic Steatohepatitis (NASH) is an advanced form of nonalcoholic fatty liver disease (NAFLD) characterized by fat accumulation in the liver along with inflammation and liver cell damage. If left untreated, NASH can progress to fibrosis, cirrhosis, liver failure, or hepatocellular carcinoma. Closely tied to the global obesity and diabetes epidemic, NASH has become a major healthcare burden, with millions affected worldwide and no widely approved curative therapy to date. The NASH
Non-Alcoholic Steatohepatitis Treatment Market Size, Share
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033. Non-Alcoholic Steatohepatitis Treatment Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance. The Market Size Is Expected To Reach $2.67 billion In 2028
Non-Alcoholic Steatohepatitis (NASH) - Drug Pipeline Landscape, 2023
Nonalcoholic steatohepatitis (NASH) is a type of fatty liver disease. It is characterized by the accumulation of fat in the liver, inflammation, and damage. NASH can lead to cirrhosis, liver failure, and death. The exact cause of NASH is unknown, but it is believed to be associated with obesity, insulin resistance, and diabetes. Treatment of NASH is focused on weight loss, exercise, and the control of diabetes and insulin resistance. NASH
Non Alcoholic Steatohepatitis (NASH) Market Size to Hit $21,879 Million by 2028 …
According to our experience research team, Non Alcoholic Steatohepatitis (NASH) Market was valued at USD 1,569 Million in 2021, and the global Non Alcoholic Steatohepatitis (NASH) industry is projected to reach a value of USD 21,879 Million by 2028, at a CAGR of 60.4% during the forecast period 2022-2028 The report is focused on gaining various Non Alcoholic Steatohepatitis (NASH) market trends, dynamics, growth drivers, opportunities, weaknesses, strengths, and threats restraining
Nonalcoholic Steatohepatitis Treatment Market Analysis
As per the research conducted by GME, the Global Nonalcoholic Steatohepatitis Treatment Market will grow with a CAGR value of 39.1% by 2026. Over the forecast era, the production of NASH biomarkers is expected to be aided by increasing demand for non-invasive diagnostic tools and increased patient awareness. The low use of invasive procedures for disease diagnosis is due to the high cost of liver biopsy, its invasiveness, and patients'
Emerging Opportunities in Nonalcoholic Steatohepatitis Therapeutics Market
Global Nonalcoholic Steatohepatitis (NASH) Market: Snapshot Nonalcoholic Steatohepatitis (NASH), a syndrome found in non-alcoholic patients, causes damage to liver that is histologically akin to alcoholic hepatitis. NASH results from fat in the liver, along with inflammation. Symptoms in NASH usually do not show, but it can be severe and lead to cirrhosis, which is permanent damage to the liver. Those suffering from obesity, dyslipidemia, and glucose intolerance are most likely